Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Chugai Applies for Combination of Herceptin, Xeloda for Gastric Cancer in Japan
March 29, 2010
- Only 12% of Free Coupons for Cervical Cancer Checkups Used
March 29, 2010
- Bayer to Enhance Links between Diagnostic Imaging, Oncology BU
March 29, 2010
- Actemra Applied for Additional Indication in the US
March 29, 2010
- Olmesartan, Prasugrel to Drive Sales of Daiichi Sankyo to ¥1,150 Bil. in FY2012
March 29, 2010
- Eli Lilly Japan's Sales Up 19% in 2009
March 22, 2010
- Torii to Develop Sublingual Desensitization Therapy for Pollinosis
March 22, 2010
- Mediceo to Cut Costs Taking Advantage of ALCs
March 22, 2010
- Takara Bio Ties Up with Univ. of Pennsylvania for HIV Gene Therapy
March 22, 2010
- Morimoto Proposes Shared Manufacturing Site in Shanghai
March 22, 2010
- Pfizer Discontinues PIII Study of Figitumumab for Advanced NSCLC
March 22, 2010
- Will the Era of DI Pharmacists Arrive?
March 22, 2010
- VEGF Trap-Eye Improved Visual Acuity in Patients with DME: Bayer
March 22, 2010
- Symbicort Ranked No. 1 on GP Market
March 22, 2010
- WG to Be Created to Increase Self-Sufficiency Rate for Blood Products
March 22, 2010
- Booz & Company Proposes New Contract Manufacturing Business Model
March 22, 2010
- JMA Strongly Opposed to Promotion of “Integrated Medicine”
March 22, 2010
- Ajinomoto Pharm. to Set Out in April
March 22, 2010
- Vaccine-Related Societies to Create Consortium to Deal with Korosho
March 22, 2010
- Korosho Completes Hearings of Dispensing Pharmacy Chain Operators
March 22, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…